Effect of recombinant human APC treatment and FV Leiden mutation status on coagulation markers. Log APTT values and log D-dimer levels (fibrin degradation product) are shown for the first 7 study days in PROWESS (4 days of drug infusion, 3 days after infusion) for VL^+/– patients (A,C) and VL^–/– patients (B,D) receiving either placebo (○) or rhAPC (•). The 95% CIs are indicated. *P < .05.